Sept. 9, 2010, 5:49 PM UTC / Source: GlobeNewswire SAN FRANCISCO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a ...
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results